KMT2D and mantle cell lymphoma: In contrast to results published from the FIL-MCL0208 trial in younger MCL, we observed only a trend towards inferior outcomes for patients with disruptive KMT2D mutations, despite using an additional layer of variant curation for KMT2D, concordant with the strategy reported by Ferrero et al. [8].